

In accordance with the provisions of 37 C.F.R. §1.121(c)(1)(i), please amend claims 115-118, 122, 126, 129, 131, 132, 134, 137, 138, and 140-142 to read as follows.

~~§1~~
Sub
G2
115. (Amended) The method of claim 113, wherein the host immune response comprises a cellular and humoral immune response.

116. (Amended) The method of claim 113, wherein the host immune response comprises a cellular immune response.

117. (Amended) The method of claim 113, wherein the host immune response comprises a humoral immune response.

118. (Amended) The method of claim 113, wherein the multi-epitopic *in vivo* antigen is a soluble antigen.

~~§2~~ G2
122. (Amended) The method of claim 113, wherein the binding agent is an antibody.

~~§3~~ G2
126. (Amended) The method of claim 113, wherein contacting the multi-epitopic *in vivo* antigen comprises administering a binding agent that has been exposed to radiation.

~~§4~~ G2
129. (Amended) The method of claim 113, wherein the antigen is CA125.

~~§5~~
Sub
G2
131. (Amended) The method of claim 122, wherein the antigen is soluble circulating antigen and the antigen is contacted with a sufficient amount of antibody to present all the circulating antigen to the immune system.

132. (Amended) The method of claim 113, wherein the antigen is contacted with binding agent in an amount of from 0.1 µg to 2 mg per kg of body weight of the host.

G2
B16
134. (Amended) The method of claim 113, wherein allowing the binding agent to form a binding agent/antigen pair presents other epitopes on the antigen to the host's immune system.

G2
B17
137. (Amended) The method of claim 135, wherein the antigen is a soluble antigen.

138. (Amended) The method of claim 135, wherein the antigen is a tumor antigen.

G2
B18
140. (Amended) The method of claim 135, wherein the binding agent is a murine monoclonal antibody which does not induce isotypic HAMA induced toxicity in the host.

141. (Amended) The method of claim 113, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more imaging reagents, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

142. (Amended) The method of claim 113, wherein contacting comprises administering by any immunologically suitable route.

Please add the following new claims.

Sub
G2
B19
170. (New) The method of claim 135, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more imaging reagents, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

Sub C1
171. (New) The method of claim 135, wherein contacting comprises administering by any immunologically suitable route.

Sub G2
172. (New) The method of claim 171, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

173. (New) The method of claim 171, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

Sub C2
174. (New) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising contacting a multi-epitopic *in vivo* antigen present in a host's serum with a composition comprising a binding agent that specifically binds to an epitope on the antigen and allowing the binding agent to form a binding agent/antigen complex, wherein the binding agent/antigen complex elicits an effective host immune response against the multi-epitopic *in vivo* antigen.

Sub G2
175. (New) The method of claim 174, wherein the effective host immune response is elicited against an epitope on the binding agent/antigen complex.

176. (New) The method of claim 174, wherein the binding agent is non-radiolabeled.

177. (New) The method of claim 174, wherein the effective host immune response comprises a cellular and humoral immune response.

Sub G2
178. (New) The method of claim 174, wherein the effective host immune response comprises a cellular immune response.

179. (New) The method of claim 174, wherein the effective host immune response comprises a humoral immune response.

180. (New) The method of claim 174, wherein the multi-epitopic *in vivo* antigen is a soluble antigen.

181. (New) The method of claim 180, wherein the soluble antigen is a soluble tumor-associated antigen.

182. (New) The method of claim 180, wherein the soluble antigen is associated with a human disease or condition.

183. (New) The method of claim 182, wherein the human disease or condition is cancer.

184. (New) The method of claim 174, wherein the binding agent is an antibody.

185. (New) The method of claim 184, wherein the antibody is a murine monoclonal antibody.

186. (New) The method of claim 184, wherein the antibody does not induce isotypic HAMA-induced toxicity in the host.

187. (New) The method of claim 174, wherein the binding agent is B43.13.

188. (New) The method of claim 174, wherein contacting the multi-epitopic *in vivo* antigen comprises administering a binding agent that has been exposed to radiation.

189. (New) The method of claim 189, wherein the binding agent has been exposed to ultraviolet radiation.

190. (New) The method of claim 184, wherein the antibody comprises a native antibody.

191. (New) The method of claim 174, wherein the antigen is CA125.

192. (New) The method of claim 191, wherein the level of CA125 in the host's serum is greater than 100 U/ml.

193. (New) The method of claim 184, wherein the antigen is soluble circulating antigen and the antigen is contacted with a sufficient amount of antibody to present all the circulating antigen to the immune system.

194. (New) The method of claim 174, wherein the antigen is contacted with binding agent in an amount of from 0.1 μ g to 2 mg per kg of body weight of the host.

195. (New) The method of claim 194, wherein the antigen is contacted with binding agent in an amount from 1 μ g to 200 μ g per kg of body weight of the host.

196. (New) The method of claim 174, wherein allowing the binding agent to form a binding agent/antigen complex presents other epitopes on the antigen to the host's immune system.

Sub
G2
197. (New) The method of claim 174, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more imaging reagents, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

198. (New) The method of claim 174, wherein contacting comprises administering by any immunologically suitable route.

199. (New) The method of claim 198, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

200. (New) The method of claim 198, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.

201. (New) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, comprising administering to the host a composition comprising a non-radiolabeled binding

agent that specifically binds to an epitope on the antigen, thereby forming a binding agent/antigen complex, whereby an effective immune response is elicited against the binding agent/antigen complex, the binding agent being present in the composition in an amount of from 0.1 μ g to 2 mg per kg of body weight of the host.

202. (New) The method of claim 201, wherein the antigen is a soluble antigen.

203. (New) The method of claim 201, wherein the antigen is a tumor antigen.

204. (New) The method of claim 202, wherein the antigen is a tumor antigen.

205. (New) The method of claim 201, wherein the binding agent is a murine monoclonal antibody which does not induce isotypic HAMA induced toxicity in the host.

206. (New) The method of claim 201, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more imaging reagents, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

207. (New) The method of claim 201, wherein contacting comprises administering by any immunologically suitable route.

208. (New) The method of claim 207, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

209. (New) The method of claim 207, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.